US20100063011A1 - Organic compounds - Google Patents
Organic compounds Download PDFInfo
- Publication number
- US20100063011A1 US20100063011A1 US12/066,518 US6651806A US2010063011A1 US 20100063011 A1 US20100063011 A1 US 20100063011A1 US 6651806 A US6651806 A US 6651806A US 2010063011 A1 US2010063011 A1 US 2010063011A1
- Authority
- US
- United States
- Prior art keywords
- methyl
- actives
- formula
- compounds
- skin care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C.[1*]c([2*])c(C#N)C1=CC=CC=C1 Chemical compound *C.[1*]c([2*])c(C#N)C1=CC=CC=C1 0.000 description 29
- IMXPYUFMPLWJNZ-UHFFFAOYSA-M O=C(O[Y])C1=C(O)C=CC=C1 Chemical compound O=C(O[Y])C1=C(O)C=CC=C1 IMXPYUFMPLWJNZ-UHFFFAOYSA-M 0.000 description 6
- KIORNKYGDVXSID-UHFFFAOYSA-N Nc(cc1ON)ccc1ON Chemical compound Nc(cc1ON)ccc1ON KIORNKYGDVXSID-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q13/00—Formulations or additives for perfume preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
Definitions
- the present invention relates to organic compounds having the ability to reduce or suppress the formation of skin irritation induced by extraneous causes, and to compositions comprising them for topical application to the skin. It further relates to a method of reducing or suppressing the onset of skin irritation by extraneous causes.
- the human skin is constantly exposed to environmental stresses, such as heat and cold, air pollution, exceptionally dry air or exaggerated UV irradiation.
- a further form of stress can come from the application of cosmetic products or personal wash products.
- certain soap acids and some surfactants, in particular anionic and cationic surfactants are known to stress the skin.
- Antiperspirant salts such as aluminum salts and zirconium salts contained in antiperspirant products, retinol and derivatives thereof contained in anti-aging products, ⁇ -hydroxy acids such as glycolic acid or lactic acid contained in anti-wrinkle products are also known to stress the skin.
- prostaglandins are mediators being formed upon a wide variety of different forms of external stress applied to the human skin, which may become apparent in redness of the skin, particularly on normal, healthy skin.
- topical application compositions such as cosmetic products and personal wash products, which suppress or reduce the formation of prostaglandins, in particular prostaglandin E 2 (PGE 2 ).
- fragrance ingredients have the ability to reduce or suppress the formation of prostaglandins in skin cells.
- the present invention refers in one aspect to the use of a compound for the preparation of topical skin care compositions for reduction of skin irritation, wherein the compound is selected from the list consisting of
- the actives for reducing skin irritation as hereinabove described may be combined with all known odorant molecules selected from the extensive range of natural products and synthetic molecules currently available, such as essential oils, alcohols, aldehydes and ketones, ethers and acetals, esters and lactones, macrocycles and heterocycles, and/or in admixture with one or more ingredients or excipients conventionally used in conjunction with odorants in fragrance compositions, for example, carrier materials, and other auxiliary agents commonly used in the art.
- ingredients are, for example, described in “Perfume and Flavor Materials of Natural Origin”, S. Arctander, Ed., Elizabeth, N.J., 1960; “Perfume and Flavor Chemicals”, S. Arctander, Ed., Vol. I & II, Allured Publishing Corporation, Carol Stream, USA, 1994; and “International cosmetic ingredient dictionary” 6 th ed., The Cosmetic, Toiletry and Fragrance Association, Inc., Washington, 1995.
- the active compound While lower concentrations of the active compound show an effect in a cell culture system, as can be seen from the examples, higher concentrations in personal care products are necessary to allow for an effective concentration on the human skin even if, for example part of the product may be removed by abrasion of clothes or may be diluted by sweat. Furthermore, the healthy skin acts as a barrier which limits the penetration of the active compounds.
- the concentration of active compound needed for efficaciousness on skin is from about 50 to 100 times higher than that needed in in-vitro tests.
- the usual perfume concentration in a topical cosmetic product is about 0.3 to 2% by weight. In general, the amount of actives applied is in the range of from 0.2 to 2% by weight, based on the end-product applied to the skin, the amounts applied usually being in the range of from 0.3 to 1% by weight.
- the present invention refers in a further aspect to fragrance compositions comprising at least 30 weight % based on the total fragrance composition of at least two actives for reducing skin irritation as hereinabove described.
- a fragrance composition comprising more than 40 weight % of active compounds should preferably contain at least 4 different actives
- a fragrance composition comprising more than 50 weight % of active compounds should preferably contain at least 5 different actives
- a fragrance compositions comprising more than 60 weight % of active compounds should preferably contain at least 6 different actives.
- the present invention refers to fragrance compositions comprising at least 30 weight % of at least three, four or five actives for reducing skin irritation.
- the fragrance composition according to the present invention comprises at least two, three or four actives of which are selected from a different group of compounds, namely group (a), (b), (c), (d), (e), and (f) as hereinabove described.
- fragrance compositions comprising a compound of formula (a) and a compound of formula (b), and fragrance compositions comprising a compound of formula (c) and a compound of formula (d) or (d′).
- fragrance compositions which are both hedonically attractive and which have irritation reducing properties may be prepared, for example, if the composition comprises at least four active compounds, each of which is selected from a different group of compounds.
- topical skin care compositions such as cosmetic products and personal wash products, comprising about 0.2 to about 3 weight %, preferably about 0.5 to about 2.5 weight % of a fragrance composition, the fragrance composition containing at least 30 weight % of at least two actives selected from the group (a), (b), (c), (d), (e), and (f) as hereinabove described, with the proviso that the topical skin care composition comprises at least 0.2 weight % of actives based on the total amount of the skin composition.
- topical skin care compositions wherein the fragrance composition containing a compound of formula (a) and a compound of formula (b), and topical skin care composition wherein the fragrance composition containing a compound of formula (c) and a compound of formula (d) or (d′).
- the present invention is directed to a method of reducing the onset of skin irritation by applying to the skin an effective amount of a topical skin care composition comprising a fragrance composition, the fragrance composition containing at least 30 weight % based on the total fragrance composition of at least two actives as defined hereinabove, with the proviso that the topical skin care composition comprises at least 0.2 weight % of actives based on the total amount of the skin composition.
- an “effective amount” is generally achieved if about 5-50 mg/cm 2 skin or about 0.05 to about 0.5 mm thick film of the topical skin product is applied to the skin.
- the expression “at least 30 weight %” includes fragrance compositions comprising at least 35, 40 or even 45 or 50 weight % of at least two actives as defined hereinabove.
- actives and “active compounds” as used within the meaning of the present invention refers to all compounds selected from the list of compounds of formula (a), (b), (c), (d), (d′), (e) and 2-heptylcyclopentanone, 2-ethoxynaphthalene, 2-methoxynaphthalene, 1-methoxy-4-(prop-1-enyl)benzene and 1-(cyclopropylmethyl)-4-methoxybenzene.
- Topical skin care compositions of the present invention may be divided into two classes of products, that is, cosmetic products and topical washing products, and may include but is not limited to antiperspirants, deodorants, day and night creams, shaving products, hand creams, body lotions, hair shampoo and conditioners, lipsticks, after-sun products, hand lotions, foundation creams, moisturizing creams, skin food, skin tonics, skin lightening products and overnight facial masks.
- the compositions may be in any form. These forms may include lotions, creams, sticks, roll-on formulations, mousses, aerosol sprays, pad-applied formulations, powders, tonics, and emulsions (oil-in-water, water-in-oil, or mixed emulsion systems).
- NHEK Normal human epidermal keratinocytes
- keratinocyte growth medium supplemented with 10% heat inactivated fetal calf serum at a humidity of 98% in a 5% carbon dioxide atmosphere.
- a confluent culture was trypsinated and adjusted to a density of 5 ⁇ 10 4 cells/ml.
- the cells were then seeded in the same medium but with only 1% fetal calf serum in 24 well plates and cultivated for a period of 48 h.
- a model irritating agent was then applied to the cells by adding calcimycin to a final level of 2.5 ⁇ M.
- the individual compounds as listed below, dissolved in DMSO were added simultaneously. The final concentration of the compounds was 50 ⁇ M or 10 ⁇ M, the final DMSO concentration was adjusted to 1% (v/v). Parallel treatments received no calcimycin (non-irritated control) or calcimycin without compounds according to the present invention (irritated control). The DMSO concentration was adjusted to 1% in all these control treatments. After 24 h incubation, the supernatant of the cells was harvested, diluted 1:1 and added to an enzyme linked immunoassay kit for the specific detection of prostaglandin E 2 as a marker of cellular irritation (Product # 404110, Neogen corporation, Lexington Ky. 40505, USA). The prostaglandin levels in treated cell cultures were compared to the irritated and non-irritated control cultures in order to determine the relative inhibition of PGE 2 formation. Results for the individual compounds are listed below.
- the fragrance composition No. 7 comprises 37.2 weight % of actives.
- Keratinocytes were grown in 24 well plates and irritated with calcimycin as described in example 1. Fragrance compositions of example 2 were dissolved in DMSO and added to the cultures simultaneously. Inhibition of PGE 2 formation was measured as described in example 1. The results are listed in Table 1.
- a hydrogel was prepared as follows:
- An antiperspirant was formulated according the following formulation:
- antiperspirants formulated with conventional perfumes led to significantly enhanced PGE 2 formation indicating an irritating nature of these products to the human skin, whereas upon treatment of EpiDerm with antiperspirants containing the inventive fragrance composition, no significantly enhanced PGE 2 levels were detected. All epidermal cultures retained 100% of the cellular viability showing that all the products are not cytotoxic.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0518558.2A GB0518558D0 (en) | 2005-09-12 | 2005-09-12 | Improvements in or related to organic compounds |
GB0518558.2 | 2005-09-12 | ||
PCT/CH2006/000481 WO2007030961A2 (en) | 2005-09-12 | 2006-09-08 | Topical compositions for reducing skin irritation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CH2006/000481 A-371-Of-International WO2007030961A2 (en) | 2005-09-12 | 2006-09-08 | Topical compositions for reducing skin irritation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/006,791 Division US9440097B2 (en) | 2005-09-12 | 2011-01-14 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100063011A1 true US20100063011A1 (en) | 2010-03-11 |
Family
ID=35221322
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/066,518 Abandoned US20100063011A1 (en) | 2005-09-12 | 2006-09-08 | Organic compounds |
US13/006,791 Active 2030-07-18 US9440097B2 (en) | 2005-09-12 | 2011-01-14 | Organic compounds |
US15/235,587 Active 2026-09-28 US10512599B2 (en) | 2005-09-12 | 2016-08-12 | Organic compounds |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/006,791 Active 2030-07-18 US9440097B2 (en) | 2005-09-12 | 2011-01-14 | Organic compounds |
US15/235,587 Active 2026-09-28 US10512599B2 (en) | 2005-09-12 | 2016-08-12 | Organic compounds |
Country Status (8)
Country | Link |
---|---|
US (3) | US20100063011A1 (pt) |
EP (1) | EP1968531B1 (pt) |
JP (1) | JP2009509929A (pt) |
CN (1) | CN101262843B (pt) |
BR (1) | BRPI0615927B1 (pt) |
GB (1) | GB0518558D0 (pt) |
MX (1) | MX2008002811A (pt) |
WO (1) | WO2007030961A2 (pt) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110002880A1 (en) * | 2007-12-05 | 2011-01-06 | 3-D Matrix, Ltd. | Material For Wound Healing and Skin Reconstruction |
US10238592B2 (en) * | 2014-04-28 | 2019-03-26 | Givaudan S.A. | Organic compounds |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006060931A1 (en) * | 2004-12-08 | 2006-06-15 | Givaudan Sa | Organic compounds |
JP4841208B2 (ja) * | 2005-09-12 | 2011-12-21 | 高砂香料工業株式会社 | フレーバー及びフレグランス組成物 |
WO2008055372A1 (en) * | 2006-11-07 | 2008-05-15 | Givaudan Sa | Malodor counteracting compositions |
GB201021050D0 (en) * | 2010-12-13 | 2011-01-26 | Givaudan Sa | Moc compositions |
KR102104150B1 (ko) * | 2012-11-15 | 2020-04-23 | 가부시키가이샤 시세이도 | 멜라닌 생성 억제제 |
KR101796866B1 (ko) * | 2016-06-28 | 2017-11-13 | 연세대학교 산학협력단 | 시멘, 베헨산, 2-메톡시나프탈렌, 티몰 및 이들의 염으로 이루어진 군에서 선택된 어느 하나 이상을 유효성분으로 함유하는 피부보습 개선, 피부각질 제거, 피부탄력 증진, 홍반 억제, 피부주름 개선 또는 피부광노화 개선 효과를 갖는 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657700A (en) * | 1983-10-07 | 1987-04-14 | Givaudan Corporation | Fragrance compositions containing benzyl ethers |
US5389608A (en) * | 1994-05-12 | 1995-02-14 | International Flavors & Fragrances Inc. | 1-phenyl-1-cyano-C5 -C7 alkanes, organoleptic uses thereof and process for preparing same |
US6069125A (en) * | 1995-11-01 | 2000-05-30 | Givaudan Roure (International) Sa | Nitrile |
US20010005711A1 (en) * | 1999-12-21 | 2001-06-28 | Stefan Lambrecht | Perfume compositions comprising 4,8-dimethyl-3,7-nonadien-2-one |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2069861A (en) * | 1933-10-16 | 1937-02-09 | Givaudan Delawanna Inc | Alpha-alkylidene and alpha-alkyl cyclo-pentanone |
DE2617817A1 (de) * | 1976-04-23 | 1977-11-10 | Henkel & Cie Gmbh | Entzuendungshemmer fuer kosmetische praeparationen |
US4404198A (en) * | 1979-01-24 | 1983-09-13 | Beecham Inc. | Phenyl Salicylate as a topical anti-inflammatory |
NL8101739A (nl) * | 1981-04-08 | 1982-11-01 | Naarden International Nv | Parfumcomposities en geparfumeerde voorwerpen en materialen, die alkylgesubstitueerde benzylcyaniden als reukstof bevatten. |
JPS59170011A (ja) * | 1983-03-16 | 1984-09-26 | Pola Chem Ind Inc | 日焼け防止化粧料 |
DE3400342A1 (de) * | 1984-01-07 | 1985-07-18 | Henkel KGaA, 4000 Düsseldorf | Verwendung von salicylsaeureestern als riechstoffe, diese enthaltende riechstoffkompositionen, sowie neue salicylsaeureester |
DE3404310A1 (de) * | 1984-02-08 | 1985-08-08 | Henkel KGaA, 4000 Düsseldorf | Verwendung von salicylsaeureestern als riechstoffe und diese enthaltende riechstoffkompositionen |
JPS6271442A (ja) | 1985-09-25 | 1987-04-02 | 株式会社東芝 | 系統安定化装置 |
EP0311616B1 (en) * | 1986-06-17 | 1991-09-25 | Biogen, Inc. | Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents for treating diseases |
EP0545556B1 (en) | 1991-11-08 | 1997-07-23 | Quest International B.V. | Perfume composition |
JPH06271442A (ja) * | 1993-03-19 | 1994-09-27 | Shiseido Co Ltd | 皮膚外用剤 |
EP0805673A1 (en) * | 1994-10-20 | 1997-11-12 | The Procter & Gamble Company | Personal treatment compositions and/or cosmetic compositions containing enduring perfume |
US5716625A (en) * | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
WO1996030469A1 (en) * | 1995-03-25 | 1996-10-03 | Quest International B.V. | Fragrance material |
JP2000507940A (ja) * | 1996-03-22 | 2000-06-27 | ユニバーシティー オブ グエルフ | 共通の機能特性を有する化学構造をコンピューターによって設計する方法 |
US5861144A (en) * | 1997-06-09 | 1999-01-19 | The Procter & Gamble Company | Perfumed compositions for reducing body odors and excess moisture |
FR2765870B1 (fr) * | 1997-07-09 | 1999-09-03 | Rhodia Chimie Sa | Procede d'etherification d'un alcool de type benzylique |
NZ504423A (en) * | 1997-11-10 | 2003-04-29 | Cellegy Pharma Inc | Composition having enhanced penetration capabilities and irritation reducing systems |
US5888962A (en) * | 1997-11-20 | 1999-03-30 | Bush Boake Allen Inc. | Nitrile perfumery material |
PT1041991E (pt) | 1997-12-19 | 2008-10-03 | Univ New York | Tetraciclinas não antibacterianas para o tratamento de esclerose múltipla |
US6030948A (en) * | 1997-12-19 | 2000-02-29 | Mann; Morris A. | Hair regeneration compositions for treatment of alopecia and methods of application related thereto |
US6106857A (en) * | 1998-03-10 | 2000-08-22 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Fragranced cosmetic product for removal of keratotic plugs from skin pores |
GB9814648D0 (en) * | 1998-07-07 | 1998-09-02 | Quest Int | Sub-lethal perfumes |
JP2003113019A (ja) * | 2001-09-28 | 2003-04-18 | Lion Corp | 皮膚外用剤 |
US7488854B2 (en) | 2002-03-14 | 2009-02-10 | The National Institute Of Agrobiological Sciences | Diterpenoid compounds imparting stress resistance to plants |
JP4579509B2 (ja) * | 2002-08-09 | 2010-11-10 | 花王株式会社 | 香料組成物 |
US20050245407A1 (en) * | 2002-08-09 | 2005-11-03 | Kao Corporation | Fragrance composition |
DE602005007980D1 (de) * | 2004-09-16 | 2008-08-21 | Firmenich & Cie | Verwendung von Nitrilderivaten als Parfümkomponente |
WO2006060931A1 (en) * | 2004-12-08 | 2006-06-15 | Givaudan Sa | Organic compounds |
-
2005
- 2005-09-12 GB GBGB0518558.2A patent/GB0518558D0/en not_active Ceased
-
2006
- 2006-09-08 JP JP2008529445A patent/JP2009509929A/ja active Pending
- 2006-09-08 MX MX2008002811A patent/MX2008002811A/es not_active Application Discontinuation
- 2006-09-08 CN CN2006800335189A patent/CN101262843B/zh active Active
- 2006-09-08 WO PCT/CH2006/000481 patent/WO2007030961A2/en active Application Filing
- 2006-09-08 US US12/066,518 patent/US20100063011A1/en not_active Abandoned
- 2006-09-08 EP EP06775174.3A patent/EP1968531B1/en active Active
- 2006-09-08 BR BRPI0615927A patent/BRPI0615927B1/pt active IP Right Grant
-
2011
- 2011-01-14 US US13/006,791 patent/US9440097B2/en active Active
-
2016
- 2016-08-12 US US15/235,587 patent/US10512599B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657700A (en) * | 1983-10-07 | 1987-04-14 | Givaudan Corporation | Fragrance compositions containing benzyl ethers |
US5389608A (en) * | 1994-05-12 | 1995-02-14 | International Flavors & Fragrances Inc. | 1-phenyl-1-cyano-C5 -C7 alkanes, organoleptic uses thereof and process for preparing same |
US6069125A (en) * | 1995-11-01 | 2000-05-30 | Givaudan Roure (International) Sa | Nitrile |
US20010005711A1 (en) * | 1999-12-21 | 2001-06-28 | Stefan Lambrecht | Perfume compositions comprising 4,8-dimethyl-3,7-nonadien-2-one |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110002880A1 (en) * | 2007-12-05 | 2011-01-06 | 3-D Matrix, Ltd. | Material For Wound Healing and Skin Reconstruction |
US10238592B2 (en) * | 2014-04-28 | 2019-03-26 | Givaudan S.A. | Organic compounds |
Also Published As
Publication number | Publication date |
---|---|
EP1968531B1 (en) | 2014-12-31 |
CN101262843A (zh) | 2008-09-10 |
US20160346181A1 (en) | 2016-12-01 |
US9440097B2 (en) | 2016-09-13 |
CN101262843B (zh) | 2013-01-30 |
WO2007030961A2 (en) | 2007-03-22 |
GB0518558D0 (en) | 2005-10-19 |
BRPI0615927B1 (pt) | 2016-09-06 |
US10512599B2 (en) | 2019-12-24 |
EP1968531A2 (en) | 2008-09-17 |
MX2008002811A (es) | 2008-04-07 |
US20120184513A1 (en) | 2012-07-19 |
WO2007030961A3 (en) | 2007-05-03 |
BRPI0615927A2 (pt) | 2011-05-31 |
JP2009509929A (ja) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10512599B2 (en) | Organic compounds | |
EP0714281B1 (en) | Deodorant composition containing acetyl hexamethyl tetralin (tonalide) | |
EP2174645B1 (de) | Riechstoffhaltige Zusammensetzungen umfassend Cetylnonanoat und/oder Stearylnonanoat | |
US6858217B2 (en) | Stabilization of terpenoids in cosmetic compositions | |
US20070298994A1 (en) | Use of 3-Mercapto-3-Methyl-Hexan-1-Ol for Use as Malodour Standard | |
US20110104089A1 (en) | Compositions comprising fragrance substances and neopentyl glycol diisononanoate | |
AU2004218560B2 (en) | Pseudo body odor composition and perfume composition for inhibiting body odor | |
BR112016013533B1 (pt) | Composição, método para acentuar o perfil de fragrância de uma composição, método para produzir um produto para o consumidor, produto ou artigo de perfumaria para consumidor e método para modificar ou melhorar as propriedades de odor de uma superfície corporal | |
JP2004262900A (ja) | 体臭抑制香料組成物 | |
JP2003238985A (ja) | 香料組成物 | |
JP2006510646A (ja) | 皮膚明色化ジ−チアンレゾルシノール誘導体、組成物および方法 | |
EP0955035A1 (en) | Body odor preventing composition | |
US9701605B2 (en) | Organoleptic compounds | |
JPH11286423A (ja) | 体臭抑制用組成物 | |
US10435645B2 (en) | Organoleptic compounds | |
KR20070116026A (ko) | 피부 미백 방법, 조성물 및 제품 | |
JP4203019B2 (ja) | 新規な皮膚明色化剤、組成物及び方法 | |
US7968606B2 (en) | Perfume composition having sedative effect | |
RU2214223C2 (ru) | Компонент, усиливающий аромат косметической композиции | |
US11091418B2 (en) | Organoleptic compounds | |
CN114746071A (zh) | 新颖感官化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GIVAUDAN SA,SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NATSCH, ANDREAS;REEL/FRAME:021786/0414 Effective date: 20080520 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |